Drug Development Regulations White Paper 
PPD
FEBRUARY 10, 2025
In the past, these developers mostly used in-house resources for their clinical monitoring and site management capabilities, whereas today they often prefer functional service provider (FSP) or full-service outsourcing (FSO) models, or a hybrid of the two, to ensure on-time and on-budget delivery of clinical operations.
PPD
AUGUST 28, 2024
For pharmaceutical innovators and drug developers working to bring oncology therapies to market, patients are the “why” behind it all. Drug developers must consider ways to remove these barriers to enhance their ability to recruit and retain trial participants.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PPD
OCTOBER 2, 2024
A recent white paper from the PPD™ clinical research business of Thermo Fisher Scientific details how these functions have evolved over the years, moving from capabilities that were previously built up and maintained in-house, to the multiple outsourcing models available today.
The Pharma Data
SEPTEMBER 9, 2020
In order to capture and manage large amounts of data while conforming to regulations, laboratories need to transform and be digitalized by unifying data capture and providing an intuitive way of interacting with it. Develop a fully automated environment to significantly boost research efforts.
FDA Law Blog: Drug Discovery
JANUARY 4, 2023
The purpose of these town halls are to discuss topics related to OTAT-regulated products, engage with product development stakeholders, and to provide information to help stakeholders to help advance drug development. The workshop is also discussed in Cell & Gene here and here.
Expert insights. Personalized for you.
52 
Let's personalize your content